valsartan/hydrochlorthiazid actavis 160 mg / 12.5 mg
actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 12.5 mg
valsartan/hydrochlorthiazid actavis 160 mg / 25 mg
actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 25 mg
valsartan/hydrochlorthiazid actavis 320 mg / 12.5 mg
actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 320 mg / 12.5 mg
valsartan/hydrochlorthiazid actavis 320 mg / 25 mg
actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 320 mg / 25 mg
imatinib sandoz 400 mg
sandoz - københavn - imatinibmesilat - tablett, filmdrasjert - 400 mg
imatinib sandoz 100 mg
sandoz - københavn - imatinibmesilat - tablett, filmdrasjert - 100 mg
nordimet
nordic group b.v. - methotrexate - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - antineoplastiske midler - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.
paclitaxel fresenius kabi 6 mg/ ml
fresenius kabi norge as - halden - paklitaksel - konsentrat til infusjonsvæske, oppløsning - 6 mg/ ml
javlor
pierre fabre medicament - vinflunin - carcinoma, transitional cell; urologic neoplasms - antineoplastiske midler - javlor er indisert i monoterapi for behandling av voksne pasienter med avansert eller metastatisk transitional-celle karsinom i urotelakelen etter svikt av en tidligere platinholdig diett. effekt og sikkerhet av vinflunine har ikke blitt studert hos pasienter med ytelse status ≥ 2.
pacligen 6 mg/ ml
sandoz - københavn - paklitaksel - konsentrat til infusjonsvæske, oppløsning - 6 mg/ ml